| 貨號 | 規格 | 價格 | 上海 | 北京 | 武漢 | 南京 | 購買數量 |
|---|---|---|---|---|---|---|---|
S81319-2mg |
98.03% | ￥280.50 | 5 | - | - | - |
|
S81319-5mg |
98.03% | ￥425.00 | 5 | - | - | - |
|
S81319-10mg |
98.03% | ￥680.00 | 6 | - | - | - |
|
S81319-25mg |
98.03% | ￥1340.00 | 6 | - | - | - |
|
S81319-50mg |
≥98% | ￥2500.00 | 貨期：2-3天 | - | - | - |
|
S81319-100mg |
≥98% | ￥4800.00 | 貨期：2-3天 | - | - | - |
|
Bioymifi is a novel and potent small-molecule activator of the TRAIL receptor DR5 in human cancer cells.
| 產品描述： | Bioymifi is a novel and potent small-molecule activator of the TRAIL receptor DR5 in human cancer cells. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點： | Apoptosis;TNF;Apoptosis;?TNF | ||||||||||||||||||||
| 細胞實驗： | Dose-response curves of bioymifi and A2C2 in T98 g cells are plotted as a function of A2C2 or bioymifi concentration. Human glioblastoma (T98 g) cells are treated with various concentrations of A2C2 or bioymifi alone or in combination with 1 μM Smac mimetic (SM) for 48 h. The corresponding cell survival is normalized to the treatment without A2C2 or bioymifi.(Only for Reference) | ||||||||||||||||||||
| 參考文獻： | 1.Wang G, et al. Nat Chem Biol. 2013, 9(2):84-9. | ||||||||||||||||||||
| 溶解性： | DMSO:87 mM | ||||||||||||||||||||
| 保存條件： | -20℃ | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
滬公網安備 31011702002021號
危險品化學品經營許可證（不帶存儲）
營業執照(三證合一)
北京